BUDESONIDE/FORMOTEROL MAINTENANCE AND RELIEVER THERAPY: AN EFFECTIVE ASTHMA TREATMENT OPTION? EUR RESPIR J 2005; 26: 819-828. Source: Eur Respir J 2005; 26: 1191 Year: 2005
EXCLUSION OF ACTIVE MYCOBACTERIUM TUBERCULOSIS COMPLEX INFECTION WITH THE T-SPOTTM.TB ASSAY. R.M.L. VAN LEEUWEN, A.W.J. BOSSINK AND S.F.T. THIJSEN. EUR RESPIR J 2007; 29: 605-607. Source: Eur Respir J 2007; 29: 1286 Year: 2007
"PROGRESSION OF SNORING AND OBSTRUCTIVE SLEEP APNOEA: THE ROLE OF INCREASING WEIGHT AND TIME". G. BERGER, R. BERGER AND A. OKSENBERG. EUR RESPIR J 2009; 33: 338-345. Source: Eur Respir J 2009; 33: 947 Year: 2009
IMPACT OF SMOKE-FREE WORKPLACE LEGISLATION ON EXPOSURES AND HEALTH: POSSIBILITIES FOR PREVENTION. M.S. JAAKKOLA AND J.J.K. JAAKKOLA. EUR RESPIR J 2006; 28: 397-408. Source: Eur Respir J 2006 Oct 01;28(4):887-888 Year: 2006
INVASIVE PULMONARY ASPERGILLOSIS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. P. BULPA, A. DIVE AND Y. SIBILLE. EUR RESPIR J 2007; 30: 782 800. Source: Eur Respir J 2007; 30: 1236 Year: 2007
"BECLOMETHASONE/FORMOTEROL VERSUS BUDESONIDE/FORMOTEROL COMBINATION THERAPY IN ASTHMA". A. PAPI, P.L. PAGGIARO, G. NICOLINI, A.M. VIGNOLA AND L.M. FABBRI ON BEHALF OF THE INHALED COMBINATION ASTHMA TREATMENT VERSUS SYMBICORT (ICAT SY) STUDY GROUP. EUR RESPIR J 2007; 29: 682-689. Source: Eur Respir J 2008; 32: 822 Year: 2008
"TACROLIMUS FOR ANTISYNTHETASE SYNDROME WITH INTERSTITIAL LUNG DISEASE?" [REPLY LETTER]. L.P. NICOD. EUR RESPIR J 2008; 32: 245-246. Source: Eur Respir J 2008; 32: 822 Year: 2008
"FREQUENCY AND CLINICAL CHARACTERISTICS OF RAPID-ONSET FATAL AND NEAR-FATAL ASTHMA". V. PLAZA, J. SERRANO, C. PICADO, J. SANCHIS, ON BEHALF OF THE HIGH RISK ASTHMA RESEARCH GROUP. EUR RESPIR J 2002; 19: 846-852. Source: Eur Respir J 2009; 33: 1240 Year: 2009
EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. B.R. CELLI AND P.J. BARNES. EUR RESPIR J 2007; 29: 1224 1238. Source: Eur Respir J 2007; 30: 401 Year: 2007
“ASSESSING THE TREATMENT EFFECT FROM MULTIPLE TRIALS IN IDIOPATHIC PULMONARY FIBROSIS.” L. RICHELDI. EUR RESPIR REV 2012; 21: 147–151. Source: Eur Respir Rev 2012 21:263 Year: 2012
"REDUCED MITOCHONDRIAL DENSITY IN THE VASTUS LATERALIS MUSCLE OF PATIENTS WITH COPD". H.R. GOSKER, M.K.C. HESSELINK, H. DUIMEL, K.A. WARD AND A.M.W.J. SCHOLS. EUR RESPIR J 2007; 30: 73 79. Source: Eur Respir J 2007; 30: 817 Year: 2007
ANTIBIOTICS FOR CHRONIC BRONCHITIS: A META-ANALYSIS THAT SPEAKS ONLY FOUR LANGUAGES. M. MIRAVITLLES, B. CELLI AND A. ANZUETO. EUR RESPIR J 2007; 30: 815. Source: Eur Respir J 2007; 30: 1236 Year: 2007
DIFFERENCES IN HOSPITAL COURSE IN COMMUNITY ACQUIRED PNEUMONIA (CAP) ACCORDING TO ANTIBIOTIC TREATMENT Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019
FACTORS INFLUENCING PHARMACOLOGICAL TREATMENT IN COPD PATIENTS ENROLED IN AN INTEGRATED DISEASE MANAGEMENT PROGRAMME (IDMP) Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
EVALUATION OF SMALL AIRWAY DISEASE (SAD) IN ASTHMA. CONCORDANCES AND DISCREPANCES BETWEEN DIFFERENT TECHNIQUES. Source: International Congress 2019 – Clinical approach to asthma management Year: 2019
CARDIOVASCULAR RISK (CVR) AND EFFECTS ON THE QUALITY OF LIFE AFTER A PHYSICAL REHABILITATION PROGRAM ON COPD PATIENTS BASED ON THEIR PHENOTYPE: EXACERBATOR (E) OR NON-EXACERBATOR (NE) Source: Virtual Congress 2021 – Management of chronic cough and obstructive diseases Year: 2021
SURVIVAL OF THE IDIOPATHIC PULMONARY FIBROSIS (IPF) IN SPAIN. NATIONAL SEPAR REGISTRY Source: International Congress 2019 – Interstitial lung disease registries Year: 2019
"HOW MUCH IS TOO MUCH? THE TREATMENT OF MILD ASTHMA". P.M. O'BYRNE. EUR RESPIR J 2007; 30: 403 406. Source: Eur Respir J 2007; 30: 1026 Year: 2007
OCCUPATIONAL TUBERCULOSIS IN A LOW PREVALENCE COUNTRY DURING 2005-2015 Source: International Congress 2019 – Environment, work and respiratory health in occupational and environmental lung diseases Year: 2019
HEALTH RELATED QUALITY OF LIFE (HRQoL) AMONG PATIENTS WITH NON CYSTIC FIBROSIS BROCHIECTASIS (BE) IN STABLE PHASE Source: International Congress 2018 – Management of bronchiectasis and large airway diseases Year: 2018